Barclays downgraded Terns Pharmaceuticals (TERN) to Equal Weight from Overweight with a $53 price target down from $56, after the company agreed to be acquired by Merck (MRK) for $53 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Terns Pharmaceuticals downgraded to Neutral from Outperform at Mizuho
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at BMO Capital
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at Citizens
- Terns Pharmaceuticals downgraded to Hold from Buy at TD Cowen